» Articles » PMID: 35746649

Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2022 Jun 24
PMID 35746649
Authors
Affiliations
Soon will be listed here.
Abstract

HIV-1 protease (PR) is a viral enzyme that cleaves the Gag and Gag-Pol polyprotein precursors to convert them into their functional forms, a process which is essential to generate infectious viral particles. Due to its broad substrate specificity, HIV-1 PR can also cleave certain host cell proteins. Several studies have identified host cell substrates of HIV-1 PR and described the potential impact of their cleavage on HIV-1-infected cells. Of particular interest is the interaction between PR and the caspase recruitment domain-containing protein 8 (CARD8) inflammasome. A recent study demonstrated that CARD8 can sense HIV-1 PR activity and induce cell death. While PR typically has low levels of intracellular activity prior to viral budding, premature PR activation can be achieved using certain non-nucleoside reverse transcriptase inhibitors (NNRTIs), resulting in CARD8 cleavage and downstream pyroptosis. Used together with latency reversal agents, the induction of premature PR activation to trigger CARD8-mediated cell killing may help eliminate latent reservoirs in people living with HIV. This represents a novel strategy of utilizing PR as an antiviral target through premature activation rather than inhibition. In this review, we discuss the viral and host substrates of HIV-1 protease and highlight potential applications and advantages of targeting CARD8 sensing of HIV-1 PR.

Citing Articles

Activation and evasion of inflammasomes during viral and microbial infection.

Ren D, Ye X, Chen R, Jia X, He X, Tao J Cell Mol Life Sci. 2025; 82(1):56.

PMID: 39833559 PMC: 11753444. DOI: 10.1007/s00018-025-05575-2.


30 years of HIV therapy: Current and future antiviral drug targets.

Nuwagaba J, Li J, Ngo B, Sutton R Virology. 2024; 603:110362.

PMID: 39705895 PMC: 11788039. DOI: 10.1016/j.virol.2024.110362.


A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication.

Sever B, Otsuka M, Fujita M, Ciftci H Int J Mol Sci. 2024; 25(7).

PMID: 38612471 PMC: 11012182. DOI: 10.3390/ijms25073659.


Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate.

Tran T, Fanucci G Viruses. 2024; 16(2).

PMID: 38400012 PMC: 10892587. DOI: 10.3390/v16020236.


Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure.

Wu F, Simonetti F Curr HIV/AIDS Rep. 2023; 20(6):428-439.

PMID: 37955826 PMC: 10719122. DOI: 10.1007/s11904-023-00674-w.


References
1.
Johnson D, Taabazuing C, Okondo M, Chui A, Rao S, Brown F . DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018; 24(8):1151-1156. PMC: 6082709. DOI: 10.1038/s41591-018-0082-y. View

2.
Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

3.
Prabu-Jeyabalan M, Nalivaika E, Schiffer C . Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure. 2002; 10(3):369-81. DOI: 10.1016/s0969-2126(02)00720-7. View

4.
Wyma D, Jiang J, Shi J, Zhou J, Lineberger J, Miller M . Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol. 2004; 78(7):3429-35. PMC: 371074. DOI: 10.1128/jvi.78.7.3429-3435.2004. View

5.
Weber I, Wang Y, Harrison R . HIV Protease: Historical Perspective and Current Research. Viruses. 2021; 13(5). PMC: 8148205. DOI: 10.3390/v13050839. View